Celgene released preliminary, estimated results for 2009 today [See Celgene Reviews 2009 Achievements]. Since we know the results for the first three quarters, we should now have an accurate estimate for Q4 numbers.
Non-GAAP Revenues for 2009 were stated at $2.67 billion. Non-GAAP revenues by quarter were $601 million in Q1, $626 million in Q2, and $292 million in Q3. That would make Q4 revenues $751 million. That is very strong growth, especially considering that Celgene did not have a recession-related slump in 2008.
Non-GAAP EPS (earnings per share) for 2009 were stated at $2.08. By quarter they had been $0.44 for Q1, $0.46 for Q2, and $0.56 for Q3. Leaving Q4 EPS around $0.62. Again, very strong growth.
The press release also estimates 2010 revenue of $3.2 to $3.3 billion. Estimated non-GAAP EPS for 2010 is $2.55 to $2.60.
There are the usual risks and uncertainties that apply to biotechnology companies, but Celgene as a company is certainly on a roll. At today's stock price it is not as cheap as some pharmaceutical companies, but today's price will look real cheap by 2011 if current trends continue.
Celgene's main product is Revlimid for multiple myeloma, but it has other major therapies and a rich pipeline of potential future earners.
Keep diversified!
More data:
Celgene
My analyst conference summaries for Celgene
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment